RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Characterization of an adduct and its degradation product produced by the reaction of cyanoethylene oxide with deoxythymidine and DNA
Yates, JM., Sumner, S., Turner, MJ., Recio, L., & Fennell, T. (1993). Characterization of an adduct and its degradation product produced by the reaction of cyanoethylene oxide with deoxythymidine and DNA. Carcinogenesis, 14(7), 1363-1369. http://carcin.oxfordjournals.org/cgi/content/abstract/14/7/1363
Cyanoethylene oxide (CEO), the putative toxic and carcinogenic metabolite of acrylonitrile, is a direct-acting mutagen. CEO reacted with deoxythymidine (dT) to form a single adduct (3% dT modified). Using two-dimensional NMR spectroscopy and fast atom bombardment mass spectrometry, this adduct was identified as N3-(2-cyano-2-hydroxyethyl)deoxythymidine. Subsequently, degradation of the adduct yielded N3-(2,2-dihydroxyethyl)deoxythymidine, a hydrated form of N3-(oxoethyl)deoxythymidine. N3-(2-cyano-2-hydroxyethyl)deoxythymidine was also detected in the reaction of [2,3–14C]CEO with calf thymus DNA. Small UV peaks, not present in the control, were detected from the reaction of CEO with dA, dG and dC. However, neither their retention times nor spectral characteristics corresponded with the standards used in this study. Characterization of this cyano-hydroxyethyl adduct and its degradation product following in vitro exposure of nucleosides to CEO may provide insight as to the types of adducts that could be assessed as biomarkers in vivo, and the modifications responsible for the mutational effects of CEO.
